Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

A method of treatment of glaucoma, normotensive glaucoma, ocular hypertension and/or combinations thereof comprising administering a therapeutically effective amount of a compound of formula (I) to a human or animal in need thereof, wherein the compound of formula (I) is:

• in which
• A is oxygen or sulfur,
• R1 is hydrogen or a group of the formula
• in which
• # is the attachment to the oxygen-atom,
• L1 is linear (C2-C4)-alkanediyl,
• L2 is linear (C1-C3)-alkanediyl,
• R5 and R8 are identical or different and independently selected from the group consisting of hydrogen or a side group of a natural α-amino acid or its homologues or isomers,
• R6 and R9 are independently selected from hydrogen or methyl,
• R7 is hydrogen or (C1-C4)-alkyl,
• or
• R7 and R5 form together with the atoms which they are attached to a pyrrolidine- or piperidine-ring,
• R10 and R11 are identical or different and are independently selected from hydrogen or (C1-C4)-alkyl,
• wherein (C1-C4)-alkyl may be substituted with one group selected from hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino or di-(C1-C4)-alkylamino,
• or
• R10 and R8 form together with the atoms which they are attached to a pyrrolidine- or piperidine-ring,
• and
• R12 is hydrogen or hydroxycarbonyl,
• R2 is hydrogen or a group of the formula —CH2OR1,
• wherein R1 is defined as above,
• R3 is hydrogen, methyl or ethyl,
• R4 is hydrogen, methyl or ethyl,
• or
• R3 and R4 form together with the nitrogen-atom, which they are bound to, a azetidine-, pyrrolidine- or piperidine-ring,
• wherein the azetidine-, pyrrolidine- or piperidine-ring may be substituted with one or 2 substituents independently selected from the group fluoro, trifluoromethyl, methyl, ethyl, methoxy and ethoxy,
• or a salt thereof.